IDXX — IDEXX Laboratories, Inc. stock price, charts and financials

QT30IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
515.15
-5.06-0.97%
IDXXQT30IDEXX Laboratories, Inc.·NASDAQ
515.15-0.97%
News
Down 1.0% — IDEXX Laboratories, Inc. $IDXX Stake Boosted by California State Teachers Retirement System (defenseworld.net).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500, NDXP/E36.48EPS (ttm)14.12Insider Own0.91%Shs Outstand78.88MPerf Week-5.50%
Market Cap40.64BForward P/E30.72EPS next Y16.77Insider Trans-0.31%Shs Float78.58MPerf Month-13.53%
Enterprise Value41.51BPEG2.47EPS next Q3.71Inst Own66.43%Short Float2.47%Perf Quarter-11.01%
Income1.14BP/S8.92EPS this Y4.61%Inst Trans0.00%Short Ratio2.95Perf Half Y-13.98%
Sales4.55BP/B25.19EPS next Y13.51%ROA33.11%Short Interest1.94MPerf YTD-23.85%
Book/sh20.45P/C-EPS next 5Y14.76%ROE71.96%52W High770.03 -33.10%Perf Year-21.09%
Cash/sh2.50P/FCF33.77EPS past 3/5Y17.66% 14.28%ROIC40.94%52W Low511.16 0.78%Perf 3Y0.75%
Dividend Est.-EV/EBITDA25.67Sales past 3/5Y8.53% 9.72%Gross Margin62.45%Volatility2.90% 2.65%Perf 5Y-23.54%
Dividend TTM-EV/Sales9.11EPS Y/Y TTM32.33%Oper. Margin32.03%ATR (14)16.34Perf 10Y359.59%
Dividend Ex-Date-Quick Ratio0.87Sales Y/Y TTM16.83%Profit Margin25.03%RSI (14)34.63Recom2.48
Dividend Gr. 3/5Y-Current Ratio1.17EPS Q/Q17.63%SMA20-5.97%Beta1.53Target Price665.00
Payout0.00%Debt/Eq0.67Sales Q/Q9.74%SMA50-7.53%Rel Volume0.87Prev Close520.21
Employees11,000LT Debt/Eq0.36EarningsNov 02SMA200-14.92%Avg Volume623.61KPrice515.15
IPO DateJun 21, 1991Option/ShortYes / YesEPS/Sales Surpr.8.28% 1.36%Net Debt/EBITDA0.56Volume542,707Change-0.97%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-11-26ReiteratedBarclaysOverweight$800$710
Jul-27-26ReiteratedUBSNeutral$640$620
Apr-28-26ReiteratedUBSNeutral$730$640
Feb-09-26ReiteratedPiper SandlerNeutral$750
Feb-05-26ReiteratedBarclaysOverweight$850$800
Feb-03-26ReiteratedBTIGBuy$830$800
Feb-03-26ReiteratedUBSNeutral$750$730
Dec-08-25InitiatedBarclaysOverweight$590$850
Nov-04-25ReiteratedJefferies$830
Nov-04-25ReiteratedMorgan StanleyOverweight$722$805
Latest News· Times ET
Sep-08-26
Sep-03-26
Aug-31-26
Aug-26-26
Aug-25-26
Aug-24-26
Aug-21-26
Aug-20-26
Aug-19-26
Aug-18-26
Aug-14-26
Aug-12-26
Aug-11-26
Company

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

Ownership
Total institutional ownership66.43%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue4,5544,3043,898
Cost of Goods Sold Incl. D&A1,7091,6441,519
Gross Profit2,8432,6602,379
Selling, General and Administrative Excl. Other1,1231,0481,031
Research and Development261251220
Other Operating Expense210
Operating Income1,4601,3601,128
Interest Expense403831
Unusual Expense
Non-Operating Income (Expense)6213
Net Income Before Taxes1,4241,3241,110
Income Taxes285265222
Consolidated Net Income1,1391,059888
Net Income From Continuing Operations1,1391,059888
Net Income1,1391,059888
EPS (Recurring)14.2413.1710.77
EPS (Basic, Before Extraordinaries)14.2413.1710.77
EPS (Diluted)14.1213.0810.67
EBITDA1,6171,4691,276
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio36.4851.7238.75
Price To Sales Ratio9.0512.578.70
Gross Margin62.4361.8061.03
Operating Margin32.0631.6028.94
Net Margin25.0124.6122.78
Shares Outstanding808082
Market Capitalization41,21254,12233,902
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$804.49$722.57$640.64$558.72$476.80 Close Price0.00M7.19M14.37M21.56M28.75MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kingsley Lawrence DDirectorSep 04 '26Sale532.082,2031,172,1789,568Sep 09
Kingsley Lawrence DDirectorSep 04 '26Option Exercise114.172,203251,51711,771Sep 09
Emerson AndrewEVP, CFO and TreasurerAug 20 '26Option Exercise178.2626547,2394,507Aug 24
FENNELL GEORGEExecutive Vice PresidentJun 01 '26Option Exercise0.00639010,717Jun 02
Vandebroek Sophie V.DirectorMay 07 '26Option Exercise0.002570905May 11
Kingsley Lawrence DDirectorMay 07 '26Option Exercise0.0033909,568May 11
Peacock KarenDirectorMay 07 '26Option Exercise0.001010102May 11
JUNIUS DANIEL MDirectorMay 07 '26Option Exercise0.0025703,561May 11
HOOLEY JOSEPH LDirectorMay 07 '26Option Exercise0.001580276May 11
SZOSTAK M ANNEDirectorMay 07 '26Option Exercise0.002570519May 11
Hunt NimrataExecutive Vice PresidentMar 03 '26Sale634.571,7581,115,57718,141Mar 05
Underberg Sharon E.EVP, GC & Corporate SecretaryMar 03 '26Option Exercise505.5319799,5897,138Mar 05
MAZELSKY JONATHAN JAYPresident and CEOFeb 27 '26Option Exercise505.5319799,58983,803Mar 02
MAZELSKY JONATHAN JAYPresident and CEOFeb 26 '26Sale657.5523,32615,338,08283,606Mar 02
MAZELSKY JONATHAN JAYPresident and CEOFeb 26 '26Option Exercise141.6023,3263,302,962106,932Mar 02
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.